Infigratinib

BridgeBio Pharma Presents Updated Six Month Results from its Phase 2 Cohort 5 Trial of Infigratinib in Achondroplasia at the Endocrine Society (ENDO) 2023 Annual Conference

Retrieved on: 
Tuesday, June 20, 2023
ENDO, Osteochondrodysplasia, FGFR3, Partnership, Cohort, PALO, Aes, Infigratinib, Hypoparathyroidism, Saint Andrew's Society, Achondroplasia, Research, IP, Șaeș, Murdoch, Patient, Physician, CXM, Cancer, Endocrine Society, Growth, Conference, Treatment, DSM-IV codes, Hypochondroplasia, Autosome, Pharmaceutical industry, Nursing, AHV

Infigratinib is an oral small molecule designed to inhibit FGFR3 and target achondroplasia at its source.

Key Points: 
  • Infigratinib is an oral small molecule designed to inhibit FGFR3 and target achondroplasia at its source.
  • The Phase 2 trial was designed to identify the dose of infigratinib that will be explored in the Phase 3 trial.
  • Our data also presents the opportunity for us to move forward quickly in initiating a Phase 3 clinical trial.
  • Based on the positive results to date, BridgeBio is underway in enrolling children in the run-in for a Phase 3 trial.

BridgeBio Announces Positive Phase 2 Cohort 5 Results of Infigratinib in Achondroplasia Demonstrating Mean Increase in Annualized Height Velocity of 3.03 cm/year with No Treatment-related Adverse Events

Retrieved on: 
Monday, March 6, 2023
ENDO, Physician, MAGIC, Hypochondroplasia, Webcast, Osteochondrodysplasia, Infigratinib, Research, Growth, Obesity, MAGIC Foundation, IP, Clinical trial, Sleep, Quality of life, FGFR3, Health, Partnership, Spinal stenosis, Murdoch, ASHG, Cohort, Achondroplasia, Calendar, Șaeș, Cancer, Aes, PALO, Safety, Silviculture, Surveying, Nursing, Pharmaceutical industry, Vaccine, AHV

Infigratinib is an oral small molecule designed to inhibit FGFR3 and target achondroplasia at its source.

Key Points: 
  • Infigratinib is an oral small molecule designed to inhibit FGFR3 and target achondroplasia at its source.
  • BridgeBio will also host an investor call on March 6, 2023, at 7:30 am ET to discuss the results from the Phase 2 study.
  • To date, the study has shown a well-tolerated safety profile, with no study drug related treatment emergent adverse events (TEAEs) in Cohort 5.
  • Based on the positive results to date, BridgeBio has started enrolling children in the run-in for a Phase 3 trial.

BridgeBio to Host Investor Call to Discuss Phase 2 Cohort 5 Data for Achondroplasia on March 6, 2023

Retrieved on: 
Friday, March 3, 2023
Achondroplasia, Mutation, Quality of life, Obstructive sleep apnea, Kyphosis, PALO, Infigratinib, Health, Cancer, Webcast, Spinal stenosis, Clinical trial, EU, FGFR3

Infigratinib is an oral small molecule designed to inhibit fibroblast growth factor receptor 3 (FGFR3) and target achondroplasia at its source.

Key Points: 
  • Infigratinib is an oral small molecule designed to inhibit fibroblast growth factor receptor 3 (FGFR3) and target achondroplasia at its source.
  • Achondroplasia impacts overall health and quality of life, leading to medical complications such as obstructive sleep apnea, middle ear dysfunction, kyphosis, and spinal stenosis.
  • To access the live webcast, please visit the “Events” page within the Investors section of the BridgeBio website at http://investor.bridgebio.com .
  • A replay of the webcast will be available on the BridgeBio website for 90 days following the event.